Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Centre Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON)

Trial Profile

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Centre Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 770 to 1070 as reported by EudraCT.
    • 10 May 2011 Actual end date changed from 1 Mar 2007 to 23 Apr 2007 as reported by EudraCT (Denmark).
    • 10 May 2011 Planned end date (25 Jan 2007) added as reported by EudraCT (Spain, Czech Republic, Hungary, United Kingdom, Italy, Denmark, Germany, Sweden).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top